The Weekly Roundup: Expanding Naloxone Access (3.15.19)
In a close vote, an advisory panel has recommended that practitioners co-prescribe naloxone with opioid prescriptions, and the recommendation is currently under review by the FDA. Health and Human Services has echoed the recommendation, providing guidance to prescribe naloxone for individuals at risk of opioid overdose, “including, but not limited to: individuals who are on relatively high doses of opioids, take other medications which enhance opioid complications or have underlying health conditions.” Proponents have suggested the recommendation could promote a healthy dialogue between providers and patients. However, detractors like Mary Ellen McCann, associate professor of anesthesia at Harvard Medical School, think the measure is too expensive—and potentially ineffective.
State-by-state regulations vary, but several—Arizona, Florida, Rhode Island, Virginia, and Vermont, among them—have laws mandating that clinicians co-prescribe naloxone. From a pharmacy perspective, some have led the charge (like California), standing orders have increased throughout the country, and most states have at least enacted laws to increase access. Rhode Island, for example, will be testing a program to provide addiction care at the pharmacy instead of in physicians’ offices. The development of the recommendations and programs around the opioid epidemic are still evolving, but one thing is clear: the pharmacist’s role is growing.
Here are a few other stories that might be of interest:
- It was only a matter of time. Documentarian who has taken on doping scandals and Enron will cover the Theranos debacle.
- Need a little inspiration to make a difference in healthcare policy and pharmacy legislation? Here’s an update on who’s who in state and federal positions of leadership.
- It’s their turn. PBMs slated to take the hot seat with congressional testimony on April 3. Meanwhile, in Ohio, every pretrial discovery trick in the book is on the table.
- Buddy is back. Data and patient testimony are key to driving congressional action on healthcare legislation.
- Need a better bottom line? Check out this free webinar on MTM later this month.
[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So, we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across each week. We hope you’ll share some of your favorites, too. Drop us a line at email@example.com.
Sign up now to receive the latest independent
pharmacy news, tips, and resources.
After the acquisition of PillPack last year, Amazon has flown fairly low on the radar when it comes to its potential pharmacy business. Last week, however, the firm announced the hire of Nader Kabbani to run its fledgling pharmacy venture. Will the same Amazon executive...
Even as a widespread outbreak of measles worries health officials in the Pacific Northwest, Facebook is under fire for spreading anti-vax messages via group recommendations. The algorithms that power websites where Americans get often inaccurate health-related information from, says Rep. Adam Schiff (D-CA), “are not de...